Cancer Drug Resistance

cdr

Search

Hot Keywords

Drug Resistance Mechanisms Epigenetic Resistance in Cancer Therapy Biomarkers Pharmacogenetics of Cancer Liquid Biopsy Targeted Cancer Therapy Non-coding RNAs Kinase Inhibitors ABC Transporters

Attempts to remodel the pathways of gemcitabine metabolism: Recent approaches to overcoming tumours with acquired chemoresistance

Yuriko Saiki, ... Akira Horii

Published on: 12 Oct 2020
Improving TRAIL-induced apoptosis in cancers by interfering with histone modifications

Bao-Jie Zhang, ... Wim J. Quax

Published on: 9 Oct 2020

Submit a Manuscript

Original Articles See more

Genomic stability at the coding regions of the multidrug transporter gene ABCB1: insights into the development of alternative drug resistance mechanisms in human leukemia cells

Kevin G. Chen, ... Branimir I. Sikic

Published on: 3 Nov 2020

Identification of sequence-specific interactions of the CD44-intracellular domain with RUNX2 in the transcription of matrix metalloprotease-9 in human prostate cancer cells

Linda T. Senbanjo, ... Meenakshi A. Chellaiah

Published on: 21 Aug 2020
Development of a TCR beta repertoire assay for profiling liquid biopsies from NSCLC donors

Leisa P. Jackson, ... Gary A. Pestano

Published on: 18 Jun 2020
Albumin nanoformulations as an innovative solution to overcome doxorubicin chemoresistance

Federica Bessone, ... Roberta Cavalli

Published on: 13 Nov 2020
Dichloroacetate enhances the antitumor effect of pirarubicin via regulating the ROS-JNK signaling pathway in liver cancer cells

Xiao-Jing Yan, ... Ji-Qin Lian

Published on: 4 Sep 2020

Pretreatment inflammatory indices predict Bevacizumab response in recurrent Glioma

Alicia Martínez-González, ... Pedro C. Lara

Published on: 7 Aug 2020
Reversal of doxorubicin resistance in lung cancer cells by neferine is explained by nuclear factor erythroid-derived 2-like 2 mediated lung resistance protein down regulation

Poornima Paramasivan, ... Viswanadha Vijaya Padma

Published on: 17 Apr 2020
Microfluidic chip enables single-cell measurement for multidrug resistance in triple-negative breast cancer cells

Karan Parekh, ... Paul Chi Hang Li

Published on: 11 Mar 2020

MEK inhibition activates STAT signaling to increase breast cancer immunogenicity via MHC-I expression

Derek A. Franklin, ... Justin M. Balko

Published on: 25 Apr 2020
Quantitative analysis of taxane drug target engagement of microtubules in circulating tumor cells from metastatic castration resistant prostate cancer patients treated with CRXL301, a nanoparticle of docetaxel

Eiman Mukhtar, ... Paraskevi Giannakakou

Published on: 17 Apr 2020

Review Articles See more

The role of extracellular vesicles in acquisition of resistance to therapy in glioblastomas

Anudeep Yekula, ... Leonora Balaj

Published on: 13 Nov 2020
Cell-mediated and cell membrane-coated nanoparticles for drug delivery and cancer therapy

Serkan Yaman, ... Kytai T. Nguyen

Published on: 3 Nov 2020
3,3’-Diindolylmethane and its derivatives: nature-inspired strategies tackling drug resistant tumors by regulation of signal transduction, transcription factors and microRNAs

Bernhard Biersack

Published on: 12 Oct 2020
Attempts to remodel the pathways of gemcitabine metabolism: Recent approaches to overcoming tumours with acquired chemoresistance

Yuriko Saiki, ... Akira Horii

Published on: 12 Oct 2020

MicroRNAs in treatment-induced neuroendocrine differentiation in prostate cancer

Theresa Akoto, ... Sharanjot Saini

Published on: 12 Oct 2020
Resistance to second generation antiandrogens in prostate cancer: pathways and mechanisms

Shiv Verma, ... Sanjay Gupta

Published on: 17 Sep 2020
Overcoming the mechanisms of primary and acquired resistance to new generation hormonal therapies in advanced prostate cancer: focus on androgen receptor independent pathways

Maristella Bungaro, ... Marcello Tucci

Published on: 12 Sep 2020
The tumor microenvironment of pancreatic adenocarcinoma and immune checkpoint inhibitor resistance: a perplex relationship

Irem Sahin, ... Ibrahim Halil Sahin

Published on: 4 Sep 2020

Others See more

Nanotechnological approaches for counteracting multidrug resistance in cancer

Chiara Martinelli, Marco Biglietti

Published on: 12 Oct 2020

Application of liquid biopsy for prognostic status of cancers and drug response

Dario Marchetti

Published on: 3 Nov 2020
Aberrant DNA repair as a potential contributor for the clonal evolution in subsets of anaplastic thyroid carcinomas arising through dedifferentiation: implications for future therapeutic algorithms?

Carl Christofer Juhlin

Published on: 3 Nov 2020
Can HIPEC be used against platinum-resistance and for inducing sensitivity to PARP inhibitors in ovarian cancer?

Thales Paulo Batista, Graziela Zibetti Dal Molin

Published on: 10 Jul 2020
Platinum drug sensitivity and resistance in testicular germ cell tumors: two sides of the same coin

Pasquale Rescigno, ... Giovannella Palmieri

Published on: 16 Jun 2020

Most Cited Papers In Last Two Years See more

How to overcome ATP-binding cassette drug efflux transporter-mediated drug resistance?

Adrian C. Jaramillo, ... Godefridus J. Peters

Published on: 19 Mar 2018

MicroRNAs in neuroblastoma tumorigenesis, therapy resistance, and disease evolution

Natarajan Aravindan, ... Sheeja Aravindan

Published on: 19 Dec 2019
Mechanisms of cisplatin sensitivity and resistance in testicular germ cell tumors

Ratnakar Singh, ... Michael J. Spinella

Published on: 19 Sep 2019

Resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer

Nele Van Der Steen, ... Godefridus J. Peters

Published on: 19 Dec 2018
Cancer drug resistance: a new perspective

Godefridus J. Peters

Published on: 19 Mar 2018
Improved potency of F10 relative to 5-fluorouracil in colorectal cancer cells with p53 mutations

Anthony Dominijanni, William H. Gmeiner

Published on: 19 Mar 2018

Ongoing Special Issues See more

Special Issue Ebooks See more

About The Journal

ISSN

2578-532X (Online)

Publisher

OAE Publishing Inc.

Article Processing Charge

OAE Publishing Inc. undertakes Article Processing Charge for authors
Editor-in-Chief

Godefridus J. Peters

Publishing Model

Gold Open Access

Copyright

Copyright is retained by authors
Publishing Frequency

Quarterly published

Contact Us

editorial@cdrjournal.com

Journal Data Analysis

Total publications: 179

Total article views: 462,909

Total article downloads: 63,363

Membership

COPE

Cancer Drug Resistance is a member of the Committee on Publication Ethics (COPE) and fully adhere to its Code of Conduct and to its Best Practice Guidelines.
STM

Cancer Drug Resistance is a member of and subscribes to the principles of STM. Authors of cdr can reuse a certain quantity of article contents from the chargeable publications of other STM members for free in their submissions to cdr.
ORCID

Cancer Drug Resistance is a member of ORCID and our MESAs system has been connected with ORCID. After submissions to cdr are published, they will be automatically synchronized to the authors' ORCID accounts if the authors have connected their MESAs accounts with ORCID accounts. cdr's reviewers can choose to synchronize their review records to their ORCID accounts when filling in review reports.
Crossref

Cancer Drug Resistance is a member of Crossref, which makes research outputs easy to find, cite, link, assess, and reuse.
iThenticate

All submissions to Cancer Drug Resistance are checked for plagiarism by iThenticate.
Check for updates

All published articles in Cancer Drug Resistance are enriched with a record of the current article status.

Partners